VItiligo RegisTry adUlts And chiLdren-France
Vitiligo
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- Not specified - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 100 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Vitiligo is a chronic skin disorder for which new therapeutic options, including topical and oral Janus kinase (JAK) inhibitors, are emerging. In this evolving therapeutic context, long-term follow-up of patients and documentation of their treatment history are important to better understand treatment outcomes and safety in routine clinical practice.
This study is a French multicenter pilot cohort conducted as a preliminary step toward the development of a national vitiligo registry. It aims to document the clinical course of patients with vitiligo, their treatments and treatment outcomes, and adverse events occurring during treatment. The study will also collect clinical, quality-of-life and patient-reported outcome data and explore potential factors associated with treatment failure or the occurrence of adverse events.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Patient with a diagnosis of vitiligo, with no age restriction.
- For adult participants: the patient has provided non-opposition to participation in the study.
- For participants under 18 years of age: the holders of parental authority have provided non-opposition to the child's participation in the study.
- Patient followed in the dermatology department of a participating center.
Exclusion Criteria:
- Patient under legal protection (guardianship or curatorship).
- Any difficulty in understanding or reading French that, in the investigator's opinion, could affect the validity of questionnaire completion.
- Cognitive, mental, or psychiatric disorder that, in the investigator's opinion, prevents completion of the study protocol.
Study population
Adults and children with a diagnosis of vitiligo followed in the dermatology department of one of the participating centers in France. Participants will be included regardless of age and will receive routine clinical care for vitiligo.
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Adults and pediatric Patients with vitiligo
Adults and children with a diagnosis of vitiligo followed in the dermatology department of a participating center. Participants receive routine clinical care for vitiligo. Clinical characteristics, current and previous treatments, treatment-related adverse events, disease severity, quality of life, and patient-reported outcomes are collected during follow-up
Other: Vitiligo treatments in routine clinical practice
Vitiligo treatments in routine clinical practice OTHER
Participants receive vitiligo treatments as part of routine clinical care. No treatment is assigned by the study protocol. Current and previous vitiligo treatments, including combination therapies, are documented during follow-up, together with clinical outcomes and treatment-related adverse events.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Clinical course of vitiligo under treatment assessed by T-VASI
Time frame: Baseline, 6 months, 1 year, and 2 years
Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Total Vitiligo Area Severity Index (T-VASI). This assessment will be used to monitor changes in vitiligo severity during treatment
Clinical course of vitiligo under treatment assessed by sIGA
Time frame: Baseline, 6 months, 1 year, and 2 years
Clinical course and disease severity in patients receiving currently used treatments for vitiligo, including combination therapies, will be assessed using the Investigator Global Assessment (sIGA). This assessment will be used to monitor changes in vitiligo severity during treatment
Secondary measures
Descriptive data of BMI
Time frame: Baseline
Descriptive data of BMI will be done using mean and median.
Treatment-related adverse events
Time frame: Baseline, 6 months, 1 year, and 2 years
Adverse events occurring in patients receiving currently used treatments for vitiligo, including combination therapies.
Measure of the quality of life
Time frame: Baseline, 1 year, and 2 years
EQ-5D for adults participants.
Vitiligo burden
Time frame: Baseline, 6 months, 1 year, and 2 years
Vitiligo burden will be assessed using the Vitiligo Impact Patient scale (VIPs).
Change in vitiligo disease activity assessed by the Vitiligo Signs of Activity Score (VSAS)
Time frame: Baseline, 6 months, 1 year, and 2 years
Vitiligo disease activity will be assessed using the Vitiligo Signs of Activity Score (VSAS). Changes in VSAS scores will be monitored over time to evaluate disease activity during follow-up.
Patient Self-reported Vitiligo extent (SA-VES)
Time frame: Baseline, 6 months, 1 year, and 2 years
Patients self-reported of disease extent will be assessed by the Self-Assessment Vitiligo Extent Score (SA-VES).This assessment will be used to monitor changes in the extent of vitiligo over time
Feasibility of the multicenter vitiligo registry
Time frame: Through study completion, up to 5 years
Number of participants enrolled, missing data, and participants lost to follow-up.
Measure of the quality of life
Time frame: Baseline, 1 year, and 2 years
Child DLQI for pediatric participants.
Age of participants at enrollment
Time frame: Baseline
Age of participants at enrollment will be recorded in years and summarized using descriptive statistics.
Distribution of participants by sex
Time frame: Baseline
The number and percentage of participants in each recorded sex category will be reported.
Number of participants with comorbidities
Time frame: Baseline, 1 year, and 2 years
The number and percentage of participants with at least one recorded comorbidity will be reported.
Number of participants with previous treatments for vitiligo
Time frame: Baseline
The number and percentage of participants who received treatment for vitiligo prior to enrollment will be reported.
Number of participants with a history of cancer
Time frame: Baseline, 1 year, and 2 years
The number and percentage of participants with a recorded diagnosis of cancer, including skin cancer, will be reported.
F-VASI - Facial extent of vitiligo
Time frame: Baseline, 6 months, 1 year, and 2 years
Facial vitiligo severity will be assessed using the Facial Vitiligo Area Severity Index (F-VASI). This assessment will be used to monitor changes in facial vitiligo severity over time
VNS - Patient reported Vitiligo noticeability scale (VNS)
Time frame: Baseline, 6 months, 1 year, and 2 years
Vitiligo noticeability will be assessed using the Vitiligo Noticeability Scale (VNS). This assessment will be used to monitor changes in the perceived noticeability of vitiligo over time
PHQ-4 - Patient Health Questionnaire to measure Psychological distress
Time frame: Baseline, 6 months, 1 year, and 2 years
Psychological distress will be assessed using the Patient Health Questionnaire-4 (PHQ-4). Changes in PHQ-4 scores will be monitored over time to evaluate psychological distress during follow-up
GAD-7 - Anxiety assessment
Time frame: Baseline, 6 months, 1 year, and 2 years
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7). Changes in GAD-7 scores will be monitored over time to evaluate anxiety symptoms during follow-up
PUSH-D - Stigma linked to vitiligo
Time frame: Baseline, 6 months, 1 year, and 2 years
Perceived and enacted stigma of vitiligo changes will be assessed using the PUSH-D questionnaire. Changes in PUSH-D scores will be monitored over time during follow-up
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Assistance Publique Hôpitaux de ParisCréteil, FranceStatus unknown
Study team and timeline
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Study start
- 2026-11 Estimated
- Primary completion
- 2031-11 Estimated
- Study completion
- 2031-11 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
VItiligo RegisTry adUlts And chiLdren-France
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026